Five-year relative survival by stage
The most commonly cited measure is five-year relative survival: the percentage of people still alive five years after diagnosis, compared with people of the same age who do not have cancer. For colorectal cancer, the widely published figures from the National Cancer Institute's SEER program are approximately:
| Stage at diagnosis | 5-year relative survival | What it means |
|---|---|---|
| Localized (confined to the colon or rectum) | about 91% | The cancer has not spread beyond the wall of the colon. This is where screening and early diagnosis place a patient. |
| Regional (spread to nearby lymph nodes) | about 73% | The cancer has reached regional lymph nodes but not distant organs. |
| Distant (metastasized) | about 13% | The cancer has spread to distant organs such as the liver or lungs. |
| All stages combined | about 53% | The average across every stage at diagnosis. |
Verify current figures
These percentages are rounded, are drawn from population registry data, and are updated periodically as treatment improves. For the current published numbers, see the National Cancer Institute and the American Cancer Society. See our resources page for the full list.
What these numbers do not mean
Survival statistics are averages across large populations. They cannot tell you what will happen to any individual. Two patients at the same stage can have very different outcomes depending on tumor biology, grade, response to treatment, age and general health.
Equally important: these figures describe patients diagnosed at various times in the past. Many were diagnosed years before the most current treatments became available, so the outlook for a patient diagnosed today may be better than the table suggests.
What the numbers do show: the cost of delay
Read the table again as a description of movement. A patient whose cancer is found while localized sits in a group with a very high survival rate. A patient whose diagnosis is delayed until the cancer has reached lymph nodes moves to a substantially lower rate. A patient whose diagnosis is delayed until the cancer has metastasized moves to a dramatically lower one.
That movement is not an abstraction. It is the measurable harm at the center of a delayed diagnosis case: a patient who could have been in the first row was instead diagnosed in the second or third, because a test was not ordered, a result was not followed up, or a symptom was not investigated.
How this connects to a legal claim
In a malpractice case, the question is usually not whether the patient would certainly have been cured, but whether the delay deprived them of a substantial chance of a better outcome — a concept often described as loss of chance. Survival statistics by stage are one of the tools used to measure that loss. See how a malpractice claim works and failure to diagnose.
Not medical advice
This page is general information for educational purposes and is not medical advice, diagnosis or treatment guidance. Your prognosis should be discussed with your own treating physicians.